Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITACA
2025-521008-22-00Phase 2Withdrawn
- Sponsor
- Croatian Cooperative Group for Clinical Trial Research in Oncology
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of alpelisib in breast cancer (2 arms), sponsored by Croatian Cooperative Group for Clinical Trial Research in Oncology. Primary endpoint: Exposure-adjusted incidence rate of grade 3 or 4 hyperglycemia. Planned start Feb 2025; status: withdrawn.
02
Drugs
alpelisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2025-521008-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521008-22-00.